Organogenesis Holdings Inc. Leases Disclosure

19. Leases

The Company’s leases consist primarily of real estate, equipment and vehicle leases.

The Company leases real estate for office, lab, warehouse and production space under noncancelable leases that expire at various dates through 2041, subject to the Company’s options to terminate or renew certain leases for an additional two to ten years.

The Company leases vehicles under operating leases for certain employees and has fleet services agreements for service on these vehicles. The minimum lease term for each newly leased vehicle is 367 days with renewal options. The Company may terminate the vehicle lease after the minimum lease term upon thirty days’ prior notice.

The Company also leases other equipment under noncancelable operating leases that expire at various dates through 2028, and certain equipment required for its cleanroom facilities under finance leases that expire in 2028.

On January 1, 2013, the Company entered into finance lease arrangements with 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC (subsequently, Dan Road Associates, LLC) and 275 Dan Road SPE, LLC for office and laboratory space in Canton, Massachusetts (the “Related-Party Leases”). 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC are related parties as the owners of these entities are also directors, former directors and / or stockholders of the Company.

In August 2021, the Company purchased the building (the “275 Dan Road Building”) under the lease with 275 Dan Road SPE, LLC for $6,013 and the lease was terminated. The Company recorded an asset of $4,943 to buildings within property and equipment, net, on the accompanying consolidated balance sheets. See Note 8, Property and Equipment, Net.

The remaining three Related-Party Leases were set to terminate on December 31, 2022 and each contained a renewal option for a five-year period. In November 2021, the Company exercised the option to extend the leases for an additional five years through December 2027, and at such time, remeasured the right of use assets and lease liabilities associated with the operating

leases. In December 2025, the Company entered into separate first amendments to lease agreements with 65 Dan Road SPE, LLC and Dan Road Associates, LLC (the “2025 Lease Amendments). The 2025 Lease Amendments extend the lease term of each lease for five years to December 31, 2032. Rental rate for 2028 will be the greater of (i) 103% of the 2027 rental rate, or (ii) the fair market rental rate as of January 1, 2028 to be determined by July 1, 2027, and rental rate will increase 3% annually thereafter. The Company remeasured the right of use assets and lease liabilities based on the market rental rate on the date of remeasurement resulting in aggregate increase in right of use assets and lease liabilities of $24,211. The classification for these leases did not change. The 2025 Lease Amendments provide an additional renewal option under each lease for an additional two-year term ending on December 31, 2034, which are not considered probable of exercise.

In November 2024, the Company entered into a lease for a facility in Smithfield, Rhode Island, comprising manufacturing and office space (“Smithfield Facility”). The initial lease term is approximately sixteen years, with two ten-year renewal options, not considered probable of exercise at lease inception, and a right of first offer to purchase the Smithfield Facility in the event that its owner markets it for sale. On April 29, 2025, the Company entered into definitive agreements related to certain state and local tax incentives for its Smithfield Facility and, as a result, the Company no longer has the unilateral right to terminate the lease. The total undiscounted minimum lease payments are $102,645, and the Company is entitled to a tenant improvement allowance of up to $18,376 for its build out of the manufacturing space. The lease of the office space commenced at lease inception, and in connection therewith, the Company recorded a operating right-of-use asset and associated lease liability of $3,425. The build out of the manufacturing space will be completed in two phases and these two phases are accounted for as two separate lease components. Phase 1 of the build-out was substantially completed and the associated lease component commenced in December 2025. Phase 2 of the build-out is expected to be completed in 2027. Tenant improvements for the manufacturing space are lessor-owned assets. Prepaid rent assets associated with Phase 1 of $17,054 were reclassified to the finance right-of-use asset on its commencement date. Prepaid rent assets associated with Phase 2 totaled $8,451 and is included in other assets in the accompanying consolidated balance sheets at December 31, 2025. The Company recorded a finance lease right-of-use asset of $27,976 and associated lease liability of $18,894 on the commencement date of Phase 1.

During the year ended December 31, 2023, the Company terminated an existing agreement for the rental of certain medical garments. The Company recorded a loss of $559 in connection with the lease termination.

The undiscounted minimum future lease payments for Phase 2 of the Smithfield Facility totaled $78,361 as of December 31, 2025. Phase 2 of the build-out is expected to be completed in 2027, at which time the associated lease component is expected to commence.